Journal of Medical Society

ORIGINAL ARTICLE
Year
: 2021  |  Volume : 35  |  Issue : 3  |  Page : 98--102

E-test antifungal susceptibility profile of Candida spp. associated with vulvovaginal candidiasis in patients of Manipur


Sudipta Naorem1, Ajit Kumar Singh Yanglem2, Randhir Babu Singh Yendrembam3, Ranjit Singh Laiphrakpam2, Ranjana Devi Khuraijam4 
1 Microbiologist, Manipur Health Services, State Medical Services, Imphal, Manipur, India
2 Department of Obstetrics and Gynaecology, Institute of Bioresources and Sustainable Development, Imphal, Manipur, India
3 Department of Microbial Resources Division, Institute of Bioresources and Sustainable Development, Imphal, Manipur, India
4 Department of Microbiology, Regional Institute of Medical Sciences, Institute of Bioresources and Sustainable Development, Imphal, Manipur, India

Correspondence Address:
Randhir Babu Singh Yendrembam
Microbial Resources Division, Institute of Bioresources and Sustainable Development, Takyelpat, Imphal - 795 001, Manipur
India

Background and Objectives: Vulvovaginal candidiasis (VVC) is one of the most common vaginal infections during fertile period of women. An increase in the prevalence of non-albicans Candida which are resistant to commonly used antifungals has been documented. Therefore, studying the antifungal susceptibility pattern of the causative agents is of great significance in successfully treating the ailment and understanding the local data. Materials and Methods: Forty-six Candida spp. isolated from VVC patients were subjected to antifungal minimum inhibitory concentration testing for itraconazole, fluconazole, and voriconazole using E-test method. Results: Candida albicans and Candida glabrata showed 87.8% and 60% sensitivity, respectively, to itraconazole. Twenty percent of Candida parapsilosis and 40% of C. glabrata were resistant to fluconazole. Voriconazole showed higher sensitivity with 0.013 μg/ml as the minimum concentration to inhibit all Candida spp. C. glabrata noted higher minimum inhibitory concentrations against itraconazole, fluconazole, and voriconazole. Interpretation and Conclusion: Voriconazole is the drug of choice in case of fluconazole treatment failure among VVC.


How to cite this article:
Naorem S, Singh Yanglem AK, Singh Yendrembam RB, Laiphrakpam RS, Khuraijam RD. E-test antifungal susceptibility profile of Candida spp. associated with vulvovaginal candidiasis in patients of Manipur.J Med Soc 2021;35:98-102


How to cite this URL:
Naorem S, Singh Yanglem AK, Singh Yendrembam RB, Laiphrakpam RS, Khuraijam RD. E-test antifungal susceptibility profile of Candida spp. associated with vulvovaginal candidiasis in patients of Manipur. J Med Soc [serial online] 2021 [cited 2022 Jul 3 ];35:98-102
Available from: https://www.jmedsoc.org/article.asp?issn=0972-4958;year=2021;volume=35;issue=3;spage=98;epage=102;aulast=Naorem;type=0